Advanced search
Publication Cover
Xenobiotica
the fate of foreign compounds in biological systems
Volume 46, 2016 - Issue 8
Submit an article Journal homepage
370
Views
11
CrossRef citations to date
0
Altmetric
Clinical Pharmacokinetics and Metabolism

Evaluation of drug–drug interaction between henagliflozin, a novel sodium-glucose co-transporter 2 inhibitor, and metformin in healthy Chinese males

Liupeng WangCenter of Drug Metabolism and Pharmacokinetics, China Pharmaceutical University, Nanjing, P.R. China,
,
Chunyong WuDepartment of Pharmaceutical Analysis, China Pharmaceutical University, Nanjing, P.R. China,
,
Lu ShenCenter of Drug Metabolism and Pharmacokinetics, China Pharmaceutical University, Nanjing, P.R. China,
,
Haiyan LiuJiang Su Heng Rui Medcine Co, Ltd, Lianyungang, P.R. China,
,
Ying ChenJiang Su Heng Rui Medcine Co, Ltd, Lianyungang, P.R. China,
,
Fang LiuJiangsu Province Hospital of Traditional Chinese Medicine, Nanjing, P.R. China, and
,
Youqun WangDepartment of Pharmacology, China Pharmaceutical University, Nanjing, P.R. ChinaCorrespondence[email protected]
&
Jin YangCenter of Drug Metabolism and Pharmacokinetics, China Pharmaceutical University, Nanjing, P.R. China, Correspondence[email protected]
 show all
Pages 703-708 | Received 21 Sep 2015, Accepted 25 Oct 2015, Published online: 26 Nov 2015

References

  • Bailey CJ. (2011). Renal glucose reabsorption inhibitors to treat diabetes. Trends Pharmacol Sci 32:63–71.
  • Bailey CJ, Turner RC. (1996). Drug therapy – metformin. N Engl J Med 334:574–9.
  • Bhartia M, Tahrani AA, Barnett AH. (2011). SGLT-2 inhibitors in development for type 2 diabetes treatment. Rev Diabet Stud 8:348–54.
  • Brunton SA. (2015). The potential role of sodium glucose co-transporter 2 inhibitors in the early treatment of type 2 diabetes mellitus. Int J Clin Pract 69:1071–87
  • Graham GG, Punt J, Arora M, et al (2011). Clinical pharmacokinetics of metformin. Clin Pharmacokinet 50:81–98.
  • He YL, Sabo R, Picard F, et al. (2009). Study of the pharmacokinetic interaction of vildagliptin and metformin in patients with type 2 diabetes. Curr Med Res Opin 25:1265–72.
  • Kasichayanula S, Liu X, Shyu W, et al. (2011). Lack of pharmacokinetic interaction between dapagliflozin, a novel sodium-glucose transporter 2 inhibitor, and metformin, pioglitazone, glimepiride or sitagliptin in healthy subjects. Diabetes Obes Metab 13:47–54.
  • Kaushal S, Singh H, Thangaraju P, et al. (2014). Canagliflozin: a novel SGLT2 Inhibitor for type 2 diabetes mellitus. N Am J Med Sci 6:107–13.
  • Liu A, Coleman SP. (2009). Determination of metformin in human plasma using hydrophilic interaction liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 877:3695–700.
  • Neumiller JJ. (2014). Empagliflozin: a new sodium-glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. Drugs Context 3:212–62.
  • Sasaki T, Seino Y, Fukatsu A, et al. (2015). Absence of drug-drug interactions between luseogliflozin, a sodium-glucose co-transporter-2 inhibitor, and various oral antidiabetic drugs in healthy Japanese males. Adv Ther 32:404–17.
  • Scheen AJ. (1996). Clinical pharmacokinetics of metformin. Clin Pharmacokinet 30:359–71.
  • Scheen AJ. (2014a). Drug–drug interactions with sodium-glucose cotransporters type 2 (SGLT2) inhibitors, new oral glucose-lowering agents for the management of type 2 diabetes mellitus. Clin Pharmacokinet 53:295–304.
  • Scheen AJ. (2014b). Evaluating SGLT2 inhibitors for type 2 diabetes: pharmacokinetic and toxicological considerations. Expert Opin Drug Metab Toxicol 10:647–63.
  • Tucker GT, Casey C, Phillips PJ, et al. (1981). Metformin kinetics in healthy subjects and in patients with diabetes mellitus. Br J Clin Pharmacol 12:235–46.
  • Turner RC, Cull CA, Frighi V, et al. (1999). Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 281:2005–12.
  • Wang Y, Tang Y, Gu J, et al. (2004). Rapid and sensitive liquid chromatography-tandem mass spectrometric method for the quantitation of metformin in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci 808:215–19.
  • Whalen K, Miller S, Onge ES. (2015). The role of sodium-glucose co-transporter 2 inhibitors in the treatment of type 2 diabetes. Clin Ther 37:1150–66.
  • Whiting DR, Guariguata L, Weil C, et al. (2011). IDF Diabetes Atlas: Global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract 94:311–21.
  • Wright EM, Hirayama BA, Loo DF. (2007). Active sugar transport in health and disease. J Intern Med 261:32–43.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.